Lupin has received final approval from the US health regulator for marketing Norgestimate and Ethinyl Estradiol tablets in the US market.
Highlights
- Pharma Major Lupin Ltd said it received final approval from USFDA to market Norgestimate and Ethinyl Estradiol Tablets.
- Norgestimate and Ethinyl Estradiol Tablets are used as contraception to prevent pregnancy.
- The approved product will be manufactured at Lupin’s Pithampur facility.
Norgestimate and Ethinyl Estradiol Tablets are AB rated generic equivalent of Janssen Pharmaceuticals Inc.’s Ortho-Cyclen 28 Tablets .
Norgestimate and Ethinyl Estradiol Tablets are used as contraception to prevent pregnancy.
It causes changes in cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus.
The approved product will be manufactured at Lupin’s Pithampur facility.
The FDA is responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, etc.
For the financial year ended 31st March, 2016, Lupin’s Consolidated sales and Net profit stood at Rs 136,539 mln ($ 2.09 billion) and Rs 22,607 mln ($ 345 million) respectively.
Source-Medindia